Chronic viral infection promotes efficient germinal center B cell responses

FALLET, Bénédict, et al.

Abstract

Persistent viral infections subvert key elements of adaptive immunity. To compare germinal center (GC) B cell responses in chronic and acute lymphocytic choriomeningitis virus infection, we exploit activation-induced deaminase (AID) fate-reporter mice and perform adoptive B cell transfer experiments. Chronic infection yields GC B cell responses of higher cellularity than acute infections do, higher memory B cell and antibody secreting cell output for longer periods of time, a better representation of the late B cell repertoire in serum immunoglobulin, and higher titers of protective neutralizing antibodies. GC B cells of chronically infected mice are similarly hypermutated as those emerging from acute infection. They efficiently adapt to viral escape variants and even in hypermutation-impaired AID mutant mice, chronic infection selects for GC B cells with hypermutated B cell receptors (BCRs) and neutralizing antibody formation. These findings demonstrate that, unlike for CD8+ T cells, chronic viral infection drives a functional, productive, and protective GC B cell response.


DOI: 10.1016/j.celrep.2019.12.023
PMID: 31995746
Chronic Viral Infection Promotes Efficient Germinal Center B Cell Responses

Highlights

- Chronic viral infection elicits potent and sustained germinal center (GC) responses

- Chronic infection triggers prolonged plasma cell and memory B cell output from GCs

- GC B cells hypermutate efficiently and are potently selected in chronic infection

Authors

Bénédicte Fallet, Yi Hao, Marianna Florova, ..., Jean-Claude Weill, Claude-Agnès Reynaud, Daniel D. Pinschewer

Correspondence
daniel.pinschewer@unibas.ch

In Brief

Fallet et al. used AID fate-mapping to compare germinal center responses to chronic and acute viral infection. Germinal center B cells in chronic infection hypermutate efficiently, adapt to viral variants, and yield more antibody-secreting cells and memory B cells for longer time periods than found in acute infection, enabling neutralizing antibody formation.
Chronic Viral Infection Promotes Efficient Germinal Center B Cell Responses

Bénédicte Fallet,1,7 Yi Hao,2,3,7 Marianna Florova,1,7 Karen Cornille,1 Alba Verge de los Aires,2 Giulia Girelli Zubani,2 Yusuf I. Ertuna,1 Victor Greiff,4,6 Ulrike Menzel,6 Karim Hammad,9 Doron Merkler,6 Sai T. Reddy,4 Jean-Claude Weill,2,9 Claude-Agnès Reynaud,2,8 and Daniel D. Pinschewer1,8,9,*

1Department of Biomedicine, Division of Experimental Virology, University of Basel, Haus Petersplatz, 4009 Basel, Switzerland
2Development of the Immune System, Institut Necker-Enfants Malades, Institut National de la Santé et de la Recherche Médicale, U1151-Centre National de la Recherche Scientifique, UMR 8253, faculté de médecine Paris Descartes, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
3Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4Department of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland
5Department of Immunology, University of Oslo, Oslo, Norway
6Department of Pathology and Immunology, Division of Clinical Pathology, University & University Hospital of Geneva, Geneva, Switzerland
7These authors contributed equally
8These authors contributed equally
9Lead Contact
*Correspondence: daniel.pinschewer@unibas.ch
https://doi.org/10.1016/j.celrep.2019.12.023

SUMMARY

Persistent viral infections subvert key elements of adaptive immunity. To compare germinal center (GC) B cell responses in chronic and acute lymphocytic choriomeningitis virus infection, we exploit activation-induced deaminase (AID) fate-reporter mice and perform adoptive B cell transfer experiments. Chronic infection yields GC B cell responses of higher cellularity than acute infections do, higher memory B cell and antibody secreting cell output for longer periods of time, a better representation of the late B cell repertoire in serum immunoglobulin, and higher titers of protective neutralizing antibodies. GC B cells of chronically infected mice are similarly hypermutated as those emerging from acute infection. They efficiently adapt to viral escape variants and even in hypermutation-impaired AID mutant mice, chronic infection selects for GC B cells with hypermutated B cell receptors (BCRs) and neutralizing antibody formation. These findings demonstrate that, unlike for CD8+ T cells, chronic viral infection drives a functional, productive, and protective GC B cell response.

INTRODUCTION

Persistent viral diseases, such as HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) infection, represent major global health challenges and affect several hundred million people worldwide (WHO, 2018a, 2018b, 2018c). A commonly held concept suggests that viral persistence requires subversion of the host’s adaptive immune defense. CD8+ T cell exhaustion, caused by chronic antigenic stimulation, represents a paradigmatic example (Gallimore et al., 1998; Moskophidis et al., 1993; Zajac et al., 1998). In contrast to T cells, the effects of chronic antigenic stimulation on B cell responses to persisting viruses remain less well defined. In chronic HBV and HIV infection, the B cell compartment is subject to phenotypic alterations, with an accumulation of atypical CD21negCD27neg memory B cells and plasmablasts in peripheral blood (Burton et al., 2018; Moir and Fauci, 2014). In these patients, circulating antiviral B cells express a range of inhibitory receptors, such as FcRL4 and PD-1 (Burton et al., 2018; Moir et al., 2008; Salimzadeh et al., 2018). Moreover, HBV-specific B cells of chronically infected patients fail to differentiate into antibody-secreting cells (ASCs) upon in vitro re-stimulation and produce inadequate amounts of immunoglobulin, both of which can be partially restored by PD-1 blockade (Burton et al., 2018; Salimzadeh et al., 2018). Impaired antibody responses to vaccination with third-party antigens (Malaspina et al., 2005) and a shortened life span of memory B cells (Wheatley et al., 2016) can be interpreted to reflect generalized suppression of the humoral immune system in HIV-infected individuals. Similarly, chronic lymphocytic choriomeningitis virus (LCMV) infection in mice is associated with suppressed antibody responses to third-party antigens (Bergthaler et al., 2010; Leist et al., 1988). Counterintuitively, however, significant LCMV neutralizing antibody (nAb) responses are typically elicited under conditions of chronic infection but only rarely when acute LCMV infection is efficiently cleared (Eschili et al., 2007). Analogously, broadly neutralizing antibody (bnAb) responses to HIV itself are most commonly found in patients with long-term uncontrolled viremia (Rusert et al., 2016). These findings raised the possibility that, unlike for CD8 T cell responses, high levels of persisting viral antigen may result in an efficient antiviral germinal center (GC) B cell response. In line with this hypothesis, the spontaneous resolution of HBV infection is associated with the formation of protective anti-HBs antibodies (Guidotti et al., 2015), and evidence is accumulating that...
spontaneous HCV clearance relies on the timely formation of bnAbs (Kinchen et al., 2018; Osburn et al., 2014; Pestka et al., 2007; Raghuraman et al., 2012). Of note, in this context, the envelope proteins of HIV, HCV, and LCMV represent challenging targets for antibody neutralization because of structural immune evasion features, such as prominent glycan shields (Helle et al., 2010; Sommerstein et al., 2015; Wei et al., 2003). Accordingly, these viral envelope proteins commonly fail to induce potent nAb responses when presented to the immune system in the context of vaccination (Law et al., 2013; Pinschewer et al., 2004; Rose et al., 2000; Sommerstein et al., 2015), but they do so in the context of chronic infection (Bergthaler et al., 2009; Eschli et al., 2007; Kinchen et al., 2018; Osburn et al., 2014; Pestka et al., 2007; Raghuraman et al., 2012; Richman et al., 2003; Ruset et al., 2016). Taken together, these observations raised the possibility that the humoral immune system meets the challenge of glycan-shielded antigens preferentially under conditions of chronic viremic infection. Such a response pattern—weak in vaccination and acute infection but potent in chronic infection—would seem counter-intuitive in light of the opposite findings for CD8 T cells. Only limited information is, however, available on the functional efficiency of antiviral GC B cell responses in chronic viral infection.

At the onset of LCMV infection, antiviral B cells are largely deleted because of interferon-driven inflammation, a process also referred to as “decimation” (Fallet et al., 2016; Mosesman et al., 2016; Sammicheli et al., 2016). In light of the finding that naive B cells can readily be recruited into an ongoing antiviral response (Doria-Rose et al., 2014; Schweier et al., 2019), we and others have proposed that antiviral B cell responses in the chronic phase of infection rely on a repertoire replenishment by new bone marrow emigrants (Doria-Rose et al., 2014; Fallet et al., 2016; Zeilweger et al., 2006). Pioneering studies on chronic bacterial and parasitic infections have revealed striking deviations from the “canonical” B cell response as it has been defined in protein-adjuvant immunizations. A dominance of very-low-affinity B cell clones at the onset of the response and their subsequent extrafollicular affinity maturation was observed in chronic murine salmonellosis (Di Niro et al., 2015). In similar violation of commonly held concepts, hypermutated immunoglobulin (Ig) M+ memory B cells were found to dominate the recall response to *Plasmodium* parasites (Krishnamurty et al., 2016), altogether emphasizing the need to better understand how B cells respond to chronic microbial exposure.

Here, we investigated how viral persistence affects the functionality of the GC B cell response. We report that the neutralizing capacity of the murine LCMV-envelope-specific antibodies, as generated during chronic infection, requires their mutational maturation, analogous to human HIV and HCV neutralizing antibodies (Bailey et al., 2017; Georgiev et al., 2014; Jardine et al., 2016; Simonich et al., 2016; Wiehe et al., 2018; Xiao et al., 2009). Importantly, we found that chronic viremic infection drives a long-lived GC reaction with potent selection of hypermutated clones. The resulting output of memory B cells and plasma cells exceeded the cellular yields upon acute infection. In conclusion, our observations characterize the GC B cell responses underlying potent nAb formation in persistent viral infection. These insights should help to better mimic chronic infection when designing B cell-based vaccination approaches against persistent viral diseases.

### RESULTS

#### LCMV nAbs Arise Preferentially in Chronic Infection and Require Somatic Hypermutation

To compare B cell responses in acute and chronic infection, we made use of two genetically engineered variants of LCMV, both carrying the identical LCMV-WE strain envelope glycoprotein (WE-GP) as the sole target for nAbs. The two viruses are based on either the Armstrong (rARM) or Clone 13 backbone (rCl13) and differ in a single amino acid position of the polymerase gene, which is essential for rCl13 persistence (Bergthaler et al., 2010). High-dose intravenous (i.v.) infection with rCl13 results in protracted high-level viremia, whereas rARM, administered intraperitoneally at lower doses, represents a prototypic model of acute infection without detectable viremia (Figure 1A; Bergthaler et al., 2007; Sommerstein et al., 2015; Zajac et al., 1998). These two extremes of a spectrum, both in terms of antigen load and persistence, yet with identical antigenicity, allowed us to study the impact of viral chronicity on antiviral B cell responses in general and on the size and dynamics of the GC response in particular. When measuring antibodies against the highly glycosylated outer globular domain of WE-GP (GP-1) by ELISA, those developed continuously for a period of 60 days and reached significantly higher titers in rCl13- than in rARM-infected mice (Figure 1B). In addition, most rCl13-infected mice mounted nAbs by day 62, whereas rARM infection elicited detectable nAb responses in only a few animals and at lower titers (Figure 1C). Altogether, these findings confirmed earlier observations that protracted LCMV infection was a more potent driver of GP-1 binding and neutralizing Ab responses than acute infection (Eschli et al., 2007). For some acute viral infections, such as influenza virus or vesicular stomatitis virus, it has been shown that germline-encoded antibodies can potently neutralize and, accordingly, those responses can be mounted within a few days (Harada et al., 2003; Kalinke et al., 1996). Conversely, nAb responses to HIV or HCV typically take weeks to months before they arise (Chen et al., 1999; Richman et al., 2003). Isolated monoclonal nAbs are often substantially hypermutated, and the ability of unmutated ancestor antibodies to bind and/or neutralize the respective virus can be limited or undetectable (Xiao et al., 2009). In light of the finding that LCMV nAbs responses arose only between days 40 and 60 after infection, we hypothesized that neutralizing activity required antibody maturation by hypermutation. To test that, we studied two LCMV-neutralizing antibodies (WEN-1 and WEN-3), which we reverted to their respective, putative, unmaturated ancestor (UA) sequence (WEN-1UA and WEN-3UA). WEN-1 and WEN-3 display V(D)J sequence hallmarks previously reported for HIV bnAbs (Kwong and Mascola, 2012); the WEN-1 heavy chain features an extraordinary 25-amino-acid-long CDR3 but diverges from its UA by only 7 amino acid changes, whereas the heavy chain variable region (VH) of WEN-3 stands out for its high mutational load (33 nt mutations, 16 aa divergence from its UA; Figure S1). Both WEN-1UA and WEN-3UA bound detectably to WE-GP but only did so at ~10- to 100-fold higher concentrations than their
respective hypermutated wild-type (WT) antibody counterparts (Figure 1D). In line with impaired binding, neither of the UA antibodies retained detectable virus-neutralizing capacity (Figure 1E). LCMV envelope-binding, non-neutralizing antibodies may, however, still exert protective antiviral effects (Hangartner et al., 2006). To test whether the UA antibodies may afford antiviral protection, we passively immunized rCI13-infected mice with either hypermutated or UA antibodies on day 3 after virus inoculation (Figure 1F). When either one of the hypermutated antibodies was administered, viremia was effectively suppressed, resulting in clearance of rCI13 by day 15. In contrast, neither of the UA antibodies reduced viral loads to a detectable extent, and all mice remained viremic throughout the observation period of 20 days. Taken together, these data indicated that hypermutation of LCMV glycoprotein-specific antibodies was required for potent binding, virus neutralization, and antiviral protection.

AID Reporter System Identifies LCMV-Specific B Cells in a Polyclonal Response

To investigate the underlying cellular correlate of LCMV nAb formation, we embarked on a comprehensive long-term study of the LCMV-specific GC B cell response in rCI13- and rARMinfected mice. First, we set out to test whether our AID reporter mouse model (AIDrep [Dogan et al., 2009]) was suitable for that

Figure 1. LCMV nAbs Arise Preferentially in Chronic Infection and Require Somatic Hypermutation

(A–C) We infected mice with rCI13 or rARMin and measured viremia (A), GP1-binding IgG titers (B), and virus-neutralizing antibodies (C) from blood on the indicated days. Symbols and bars represent means ± SEM in (A), (B), and (C, left panel). The right panel in (C) shows nAb titers of individual animals on day 62. Number of biological replicates (n) = 3–15 (A), n = 5 (B), n = 12–15 (C). Number of independent experiments (N) = 3. Two-way ANOVA with Bonferroni’s post-test for multiple comparisons. *p < 0.01.

(D and E) Binding of the rCI13-neutralizing antibodies WEN-1 and WEN-3, of their respective unmutated ancestors WEN-1UA and WEN-3UA and of an irrelevant isotype control antibody to WE-GP (D). Ability of the indicated antibodies to neutralize rCI13 (E). Symbols show the means of two technical replicates. N = 2.

(F) We infected mice with rCI13 on day 0, followed by passive immunization with the indicated antibodies on day 3. Viremia was monitored. Symbols represent the means ± SEM of three to four mice (WEN-1, one representative experiment) and of four to six mice (WEN-3, two combined experiments), respectively. N = 2. See also Figure S1.
purpose, AID<sup>Cre</sup> mice are hemizygous for an engineered aicda locus (naturally encoding for activation-induced deaminase, AID), which expresses a tamoxifen (TAM)-inducible Cre recombinase (Cre-ERT2). Additionally, AID<sup>Cre</sup> mice carry a Cre-inducible EYFP reporter gene in the ROSA26 locus, such that TAM administration induces EYFP expression selectively in approximately 10%–20% of (AID expressing) GC B cells (Dogan et al., 2009).

Thereby, timed TAM administration allows for the fate mapping of the GC B cell compartment of a given time window including these cells’ progeny. Within the population of EYFP-labeled cells, we used GL7 and B220 staining to discriminate memory B cells (GL7<sup>B220+</sup>), GC B cells (GL7<sup>B220+</sup>), and plasma cells (GL7<sup>B220−</sup>). In keeping with our earlier findings (Le Gallou et al., 2018; Thai et al., 2018), EYFP-reporting GL7<sup>B220+</sup> B cells in rARM- and rCl13-infected mice were CD38<sup>−</sup> and bound biotinylated peanut agglutinin (PNA), identifying them as GC B cells, whereas GL7<sup>B220+</sup> memory B cells exhibited an inverse staining pattern (Figures S2A and S2B). To test whether TAM expressing identified virus-specific B cells, we infected AID<sup>Cre</sup> mice with rCl13, whereas control groups were given the antigenically unrelated vesicular stomatitis virus (VSV) or were left uninfected. TAM was administered to all mice on days 0, 5, and 10, with a resulting labeling window extending approximately from day 0 to day 15 after infection (Figure 2A). When analyzed on day 50, ~20% of EYFP-reporting B cells of rCl13-infected mice bound the LCMV nucleoprotein (NP) in flow cytometry (Figures 2B, 2C, and S2), which was several-fold over background of VSV-infected or uninfected controls. Given that NP represents approximately 17% of the viral proteome, these numbers were compatible with a faithful labeling of LCMV-reactive B cells in AID<sup>Cre</sup> mice. To further assess whether TAM-reporting B cells in AID<sup>Cre</sup> mice were indeed mostly LCMV-reactive, we performed adoptive B cell transfer experiments (Figure 2D). We infected AID<sup>Cre</sup> mice with either rCl13 or with Vaccinia virus (Vacc) on day 0, followed by TAM treatment as above. On day 30, we isolated splenic B cells from these donor mice, containing a population of supposedly rCl13- or Vacc-specific, EYFP-labeled B cells, respectively. These (CD45.2<sup>+</sup>) B cells were adoptively transferred into syngeneic (CD45.1<sup>+</sup>) recipients, which had been infected with either rCl13 or Vacc beforehand. The recipients were infected ahead of the transfer, rather than afterward, to avoid the “decimation” of adoptively transferred B cells by interferon-driven inflammation (Fallet et al., 2016; Moseman et al., 2016; Sambmicheli et al., 2016). When analyzed 6 days after transfer, sizeable populations of EYFP<sup>+</sup> CD138<sup>−</sup> B cells and EYFP<sup>+</sup> CD138<sup>+</sup> antibody-secreting cells (ASCs) were detected in rCl13-infected recipients, but not in Vacc-infected recipients, of B cells from rCl13-infected donors and vice versa (Figures 2E and 2F). This result confirmed that AID<sup>Cre</sup> mice identified mostly virus-specific B cells rather than non-specifically activated polyreactive B cells, validating the AID<sup>Cre</sup> mouse model for our ambitions to study LCMV-specific GC B cell responses.

### Chronic Infection Triggers a Sustained GC Response with Prolonged Plasma Cell and Memory B Cell Output

To compare the generation and maintenance of B cell responses in chronic and acute viral infection, we inoculated groups of AID<sup>Cre</sup> mice with either rCl13 or rARM and treated them with TAM in a manner corresponding to labeling windows from day 0–10 (early), day 10–20 (intermediate), or day 30–40 (late), respectively (Figure 3A). On day 60 after infection, we enumerated EYFP<sup>+</sup> GL7<sup>B220+</sup> GC B cells, which consistently co-expressed CD95, EYFP<sup>+</sup> GL7<sup>B220+</sup> memory B cells (MemB cells) and EYFP<sup>+</sup> GL7<sup>B220+</sup> ASCs (Figures 3B, S3A, and S3B). Thereby, we assessed LCMV-specific B cells and plasma cells fulfilling two criteria: first, these cells or their precursors had expressed AID in the early, intermediate, and late labeling windows, respectively; and second, they were still present at the day-60 time point of analysis as GC B cells, MemB cells, or ASCs. This experimental approach did not, however, inform about the clonal relationship among cells labeled in different time windows. We found that EYFP<sup>+</sup> GC B cells were approximately 3-fold more numerous in rCl13- than in rARM-infected mice, irrespective of the TAM-labeling window (Figure 3C).

Conversely, the total number of GC B cells in rARM- and rCl13-infected animals was not significantly different (Figure S3C). This indicated that antiviral GC responses were maintained at lower levels in acute, as compared with chronic, infection, with a proportional reduction in cells that had expressed AID during the early, intermediate, and late labeling windows (“early labeled,” “intermediate-labeled,” and “late-labeled”) cells. For the intermediate and late labeling windows, reduced virus-specific GC B cell responses in rARM-infected, as compared with rCl13-infected, mice were also reflected in a lower proportional representation of AID-reporting cells among total GC B cells (Figure S3D). In contrast, early labeled MemB cell (Figure 3D) and early labeled ASC (Figure 3E) pools were of comparable size in rCl13- and rARM-infected animals, suggesting that in the early phase after virus inoculation, the MemB cell and ASCs output of acute and chronic infection was comparable. With transition from the early to intermediate and late labeling windows, however, the MemB cell and ASC output of rARM-infected mice declined progressively, which contrasted with sustained levels in rCl13 infection. These observations found independent support in immunohistochemical analyses from spleens of early labeled mice, showing that EYFP<sup>+</sup> cells inside splenic GCs were more numerous in rCl13 than in rARM infection (Figure 3F). Taken together, these observations indicated that GC responses in chronic infection were sustained at higher levels over time and, in the long term, drove higher MemB cell and ASC output than acute infection.

### Chronic Infection Is a Potent Long-term Driver of B Cell Responses

We aimed to corroborate the hypothesis that at intermediate to late time points after virus inoculation, chronic infection was a more potent driver of B cell responses than was acute infection. For that, we performed adoptive transfer experiments with Cell Trace Violet (CTV)-labeled B cells of AID<sup>Cre</sup> mice, which express the monoclonal LCMV envelope-specific B cell receptor KL25 from a heavy chain knockin and a light chain transgene (KL25HL-AID<sup>Cre</sup> mice, CD45.1; Figure 4A). Twenty days before transfer, the syngeneic (CD45.2) recipients were infected with genetically engineered rCl13 or rARM variants (rCl13<sup>*,</sup> rARM<sup>*</sup>) carrying the N121K point mutation in their WE-GP envelope protein (WE-GP<sup>*</sup>). This envelope variant is only poorly neutralized by
Figure 2. AID Reporter System Identifies LCMV-Specific B Cells in a Polyclonal Response

(A–C) We infected Aid<sup>+</sup> mice with rCl13 or VSV on day 0 or left them uninfected. TAM was administered on days 0, 5, and 10, as schematically shown in (A). LCMV-NP binding by splenic EYFP<sup>+</sup> GL7<sup>+</sup> B cells was analyzed on day 50 (B and C). Panel (B) shows a representative FACS plot with numbers indicating the percentage of gated cells, as quantified in (C). For gating strategy, see Figure S2.

(D–F) We infected Aid<sup>+</sup> mice with rCl13 or Vacc on day 0 and treated them with tamoxifen on days 0, 5, and 10, as schematically shown in (D). On day 30, we purified B cells from spleen by magnetic cell separation and transferred them into syngeneic C57BL/6 recipients, which had been infected with rCl13 6 days before (day 24) or with Vacc 3 days earlier (day 27). Six days after transfer (day 36), we measured the expansion and plasma cell differentiation of proliferated (CTV<sup>lo</sup>) adoptively transferred EYFP-reporting B cells in the spleen (E and F). Two distinct EYFP<sup>+</sup> ASC populations in (E) correspond to different stages of maturation. EYFP-reporting cells were enumerated in (F). Representative FACS plots are gated on EYFP<sup>+</sup> B220<sup>+</sup> CD138<sup>-</sup> GL7<sup>+</sup> B cells (B) and on recipient (CD45.2<sup>+</sup>) lymphocytes in black with EYFP<sup>+</sup> CTV<sup>lo</sup> donor cells overlaid in green (E), respectively (see Figure S2). Numbers in FACS plots represent percentages of gated cells among EYFP<sup>+</sup> B220<sup>+</sup> CD138<sup>-</sup> GL7<sup>+</sup> B cells.

Bars represent means ± SEM, n = 3–4 (C) and n = 4 (F). N = 2. One-way ANOVA with Bonferroni’s post-test for multiple comparisons (C). Two-way ANOVA with Bonferroni’s post-test for multiple comparisons (F). **p < 0.01 comparing B cells; ***p < 0.01 comparing ASCs, respectively. See also Figure S2.
A

rCI13 or rARM

Early (d0-10) labeling

d0 d5

Intermediate (d10-20) labeling

d10 d15

Late (d30-40) labeling

d30 d35

d60

TAM administration (days p.i.)

TAM labeling

B

EYFP⁺ splenocytes

rARM

MemB 56.4

GCs 27.6

ASCs 15.5

rCI13

MemB 31.1

GCs 60.3

ASCs 8.34

MemB 50.3

GCs 41.5

ASCs 7.66

MemB 35.5

GCs 55.1

ASCs 9.08

MemB 32.0

GCs 58.7

ASCs 9.21

MemB 24.8

GCs 70.5

ASCs 4.49

B220

GL7

C

# EYFP⁺ GCs / 10^3 splenocytes

0 1 2 3 4 5

d0-10 (early)

TAM labeling

d10-20 (intermediate)

TAM labeling

d30-40 (late)

0.5 1.0 1.5 2.0

0.1 0.2 0.3 0.4 0.5

# EYFP⁺ MemB / 10^3 splenocytes

# EYFP⁺ ASCs / 10^3 splenocytes

F

B220

PNA

EYFP⁺

Merge

rARM

rCI13

(legend on next page)
the KL25 antibody because of only intermediate affinity binding as opposed to high-affinity interaction with WE-GP (Hangartner et al., 2008). Intermediate affinity B cell receptor interactions were chosen for these experiments with KL25HL-AID<sup>rep</sup> B cells to facilitate affinity maturation and render the experimental conditions more physiological. For induction of the AID-driven Cre reporter, the recipients were given TAM on the day of B cell transfer and again 3 days later (days 20 and 23). Within 5 days after adoptive transfer (day 25), virtually all KL25HL-AID<sup>rep</sup> B cells had diluted CTV in both chronically and acutely infected mice (Figure S4), indicating antigen-driven proliferation (Schweier et al., 2019). The proportion of KL25HL-AID<sup>rep</sup> cells, which had activated AID (EYFP<sup>+</sup>) and/or expressed the GC marker GL7, increased from day 25 to day 35 in both rCl13<sup>*</sup>- and rARM<sup>*</sup>-infected recipients (Figures 4B and S4). In addition, the EYFP/GL7 subset distribution, i.e., the proportion of KL25HL-AID<sup>rep</sup> B cells activating AID and participating in GC reactions, was similarly acute in acutely and chronically infected mice. Importantly, however, the number of KL25HL-AID<sup>rep</sup> B cell progeny recovered from chronically rCl13<sup>*</sup>-infected mice exceeded those emerging from rARM<sup>*</sup> infection by ~5-fold (Figure 4C). These numeric differences manifested in the AID-reporting (EYFP<sup>+</sup>) and non-reporting (EYFP<sup>−</sup>) compartments and were similarly prominent for GC B cells (GL7<sup>+</sup>) as they were for MemB cells (GL7<sup>+</sup>). Accordingly, KL25HL-AID<sup>rep</sup> B cells produced substantially higher antibody titers when transferred into chronically infected mice than upon transfer into acutely infected animals (Figure 4D). This suggested that B cell clones recruited into the ongoing response or generated by hypermutation at later time points after infection were better represented in the serum immunoglobulin pool of chronically, rather than acutely, infected mice. Differential expansion of the adoptively transferred KL25HL-AID<sup>rep</sup> B cell population was also evident at the histological level with markedly more EYFP<sup>+</sup> KL25HL-AID<sup>rep</sup> B cells inside GCs as well as outside GCs (Figure 4E). In summary, these experiments established that, in the time window from days 20–35 after infection, virus-specific B cells expanded more vigorously in chronically, than in acutely, infected mice. They produced more antibody and yielded approximately 5-fold more AID-reporting GC B cell and MemB cell progeny.

**Comparable V<sub>H</sub> and J<sub>H</sub> Intron Mutation Frequencies in B Cells of Acutely and Chronically Infected Mice**

Next, we investigated whether chronic and acute infection settings differed in their ability to drive B cell hypermutation. We performed adoptive transfer experiments with KL25HL-AID<sup>rep</sup> B cells on day 20 after infection and sorted GL7<sup>+</sup> GC B cell progeny on day 35, as outlined in Figure 4A. We determined both intronic sequences downstream of J<sub>H</sub> as a readout of overall AID activity in the transferred KL25HL-AID<sup>rep</sup> B cells and also KL25 V<sub>H</sub> sequences as an indicator of affinity maturation. Neither of these target sequences provided clear evidence for a differential rate of hypermutation in acute, as compared with, chronic infection (Figures 5A and 5B). This conclusion found independent support when we compared J<sub>H</sub> intronic sequences of polyclonal isotype-switched GC B cells (GL7<sup>+</sup> IgM<sup>+</sup> IgD<sup>−</sup> B220<sup>−</sup>) on day 60 after rCl13 and rARM infection (Figures S5A and S5B). Hence, we performed a detailed analysis of coding mutations in the KL25 V<sub>H</sub> region of KL25HL-AID<sup>rep</sup> B cells emerging from acute and chronic infection. We found evidence for an enrichment of recurrent mutations both in complementarity determining regions (CDRs) and framework regions (FRs) of the BCR (Figure 5C). When systematically analyzing these sequences for evidence of affinity maturation, we noted three CDRH3 mutations (W104L, F106L, and Y108S), which were found in at least four of eight individual mice infected with either rARM<sup>*</sup> or rCl13<sup>*</sup> (bold red residues in Figure 5C). With the exception of F106L, these recurrent CDRH3 mutations were found in KL25HL-AID<sup>rep</sup> B cells recovered from chronically and acutely infected animals. We recombinitely expressed the three KL25 point mutant antibodies with amino acid changes in CDRH3 (W104L, F106L, and Y108S) and assessed their ability to bind WE-GP<sup>*</sup> and to neutralize the corresponding WE-GP<sup>*</sup>-expressing virus rCl13<sup>*</sup>. KL25-W104L was the most prevalent mutant antibody (7 out of the 8 mice studied), and it bound considerably better to WE-GP<sup>*</sup> than to the parental KL25 antibody, whereas the latter was a better binder on WE-GP<sup>*</sup> (Figure 5D). Importantly, KL25-W104L neutralized rCl13<sup>*</sup> more potently than KL25-WT did, altogether indicating that the W104L mutation was acquired because of an affinity maturation on the WE-GP<sup>*</sup> envelope protein of the infecting rCl13<sup>*</sup> virus (Figure 5E). Improved WE-GP<sup>*</sup> binding and rCl13<sup>*</sup> neutralization by KL25-W104L was acquired at the expense of a relative reduction in the antibody’s capacity to bind and neutralize rCl13. Similar trends were also noted for the other two CDRH3 KL25 mutants (KL25-F106L and KL25-Y108S; Figures S5C–S5F). Taken together, these data suggested that KL25HL-AID<sup>rep</sup> B cells underwent affinity maturation upon adoptive transfer into either rCl13<sup>*</sup> or rARM<sup>*</sup> infected mice, and that this process was at least equally efficient in chronic infection as it was in acute infection.

**Potent Selection of Hypermutated B Cells in Chronically Infected Mice**

We report here that the generation of LCMV nAbs depends on hypermutation (Figures 1D–1F) and that nAbs are preferentially
mounted in chronic, as opposed to acute, infection (Figure 1C; Eschil et al., 2007). Moreover, we have previously shown that the formation of nAbs and also the control of chronic LCMV infection fail in aicda−/− mice lacking class-switch recombination and affinity maturation (Bergthaler et al., 2009). Hence, we aimed to test whether AID-driven hypermutation, which apparently functions efficiently in chronically infected mice (Figure 5), is rate limiting for nAb generation and virus control. As a model of hypermutation-impaired B cells, we made use of gene-targeted mice, which carry one deleted and one G23S-mutated allele of aicda (AIDG23S−/− mice [Wei et al., 2011]). The AID-G23S mutation allows for class switch recombination and causes a substantial

### Figure 5. Comparable V<sub>H</sub> and J<sub>H</sub> Intron Mutation Frequencies in B Cells of Acutely and Chronically Infected Mice

(A–C) We performed adoptive transfer experiment as in Figure 4, and on day 36, we sorted isotype-switched adoptively transferred KL25HL-AID<sup>rep</sup> GC B cells (CD45.1<sup>+</sup> HD104L<sup>+</sup> I<sup>−</sup>IgM<sup>−</sup>IgD<sup>−</sup>G<sup>−</sup>) by FACS for IgH locus sequencing. (A) Mutation frequencies in the J<sub>H</sub> intron as base pair (bp) changes are shown for all sequences obtained (left) as well as for mutated introns only (right). (B) Mutations in the KL25 V<sub>H</sub> gene as total amino acid changes per V sequence, for all sequences (left) or sequences with amino acid changes (right), taking only functional sequences into account. (C) All amino acid mutations collected from four rARM<sup>−</sup>- and four rC13−infected mice (708 sequences total, 85–91 sequences per mouse) are represented along the KL25 V<sub>H</sub> protein sequence (top: rC13<sup>−</sup> infection; bottom: rARM<sup>−</sup> infection). Mutations are shown in bold red letters when present in at least four individual mice (out of eight). CDR positions are shaded in gray. Bars show means ± SD, and symbols represent individual mice. n = 4, N = 1 (A–C). Unpaired two-tailed Student’s t test (A and B). ns, p > 0.05.

(D) Binding of KL25 wild-type and KL25-W104L to WE-GP and WE-GP<sup>+</sup>. Symbols in (D) and (E) show the mean of 2 technical replicates. N = 3 (D and E). See also Figure S5.

### Figure 4. Chronic Infection Is a Potent Long-Term Driver of B Cell Responses

(A) We infected syngeneic recipient mice with rARM<sup>−</sup> or rC13<sup>−</sup> on day 0, and 20 days later, we adoptively transferred CTV-labeled KL25HL-AID<sup>rep</sup> B cells. TAM was administered on the day of transfer (day 20) and on day 23.

(B and C) Five and 15 days after adoptive transfer (day 25 and day 35), we analyzed KL25HL-AID<sup>rep</sup> B cells by flow cytometry for AID reporting (EYFP<sup>+</sup>) and GC differentiation (GL7 expression). Representative FACS plots in (B) are gated on adoptively transferred proliferated B cells (CD45.1<sup>+</sup> HD104L<sup>+</sup> I<sup>−</sup>IgM<sup>−</sup>IgD<sup>−</sup>G<sup>−</sup>) cells, gating strategy in Figure S4). The average proportional representation of EYFP<sup>+</sup>GL7<sup>−</sup> (red), EYFP<sup>−</sup>GL7<sup>+</sup> (orange), EYFP<sup>−</sup>GL7<sup>−</sup> (magenta), and EYFP<sup>+</sup>GL7<sup>−</sup> (blue) subsets is displayed in pie charts. Absolute numbers of the same cell populations are shown in (C). Bars represent means ± SEM, n = 3–5.

(D) The concentration of KL25 IgG in the serum of KL25HL-AID<sup>rep</sup> B cell recipients was determined by GP-1 ELISA. Background GP-1-specific IgG levels in control mice without KL25HL-AID<sup>rep</sup> B cell transfer were at least 4-fold lower than in the respective groups of recipients. Symbols show individual mice.

(E) Histological sections from spleens of rC13− and rARM<sup>−</sup> infected mice on day 25. Scale bar: 50 μm. n = 3, N = 2.

Two-way ANOVA with Bonferroni’s post-test for multiple comparisons (C), unpaired two-tailed Student’s t test (D). *p < 0.05, **p < 0.01. See also Figure S4.
reduction in hypermutation rates (Wei et al., 2011). We infected AIDG23S/- and WT control mice with rCl13 and measured viremia (A) and rCl13-neutralizing antibodies (B) over time. To our surprise, rCl13 control in AIDG23S/- was only very modestly delayed, if at all (Figure 6A). In addition, nAb responses followed similar kinetics as in WT mice and reached comparable titers (Figure 6B). Hence, we sorted polyclonal GL7+ GC B cells on day 60 after infection for IgH locus sequencing. The analysis of JH intronic sequences as a readout of overall AID activity confirmed our expectations (Wei et al., 2011) of approximately 10-fold-reduced mutation frequencies in AIDG23S/- mice (Figure 6C). This difference between AIDG23S/- and WT mice persisted when excluding non-mutated sequences (‘‘mutated introns’’ in Figure 6C) and was also reflected in a paucity of highly mutated clones (Figure 6D). To understand how AIDG23S/- mice generated LCMV nAbs despite substantially reduced hypermutation frequencies, we determined the mutational burden in polyclonal VH sequences by unbiased high-throughput RNA sequencing (RNA-seq). In marked contrast to the intronic sequences, a very modest 1.3-fold reduction in the number of VH mutations was observed in AIDG23S/- mice (Figure 6E), with a fair representation of highly mutated clones (Figure 6F). Taken together, these findings indicated that chronic infection provides a formidable selection machinery, which, even under conditions of substantially reduced AID-driven mutation rates, yields GC B cells with highly mutated V_H sequences.

DISCUSSION

Our study establishes that the humoral immune system and GC B cell responses, in particular, are very effective at coping with chronic viral antigen exposure. Long-lived GC B cell responses, efficient selection of hypermutated clones and high MemB cell, and ASC output altogether argue against humoral immune subversion, a conclusion which finds independent support in the accompanying paper (Kräutler, 2020 [this issue of Cell Reports]). Intriguingly, this response pattern reflects the opposite of CD8 T cell exhaustion, yet, from an evolutionary standpoint, it seems logical and beneficial for the host. Exhaustion is commonly thought of as nature’s strategy to avoid fatal immunopathological consequences of inflammatory cytokine release and over-shooting T cell cytotoxicity (Frebel et al., 2012). nAb-mediated virus clearance, in contrast, is an innocuous and virtually non-inflammatory process. Immune complex disease, the only known side effect of humoral immune defense in chronic viral infection, is rare and may selectively occur in a subset of patients with genetic predispositions (Gupta and Quigg, 2015).

It, therefore, appears that, with progression to the chronic phase of viral infection, the relative efficacy of humoral immune defense increases, whereas CD8 T cell responses undergo exhaustion. Interestingly, the CD4 differentiation profiles that predominate under these respective conditions are predicted to support a shift from cellular to humoral immune defense: with progression to chronicity T helper 1 (Th1) responses become exhausted (Brooks et al., 2005; Kaufmann et al., 2007; Oxenius et al., 1998), similar to CD8+ T cells, whereas...
T follicular helper (Tfh) cells start to dominate the CD4 T cell response (Fahey et al., 2011; Feng et al., 2012; Lindqvist et al., 2012). Chronic infection also favors the emergence of Tfh cells with distinct functional profiles, such as the ability to co-produce interleukin (IL)-10 and IL-21 (Xin et al., 2018). Accordingly, potent Tfh responses represent an essential component of efficient GC reactions in the chronic infection context (Greczmiel et al., 2017; Harker et al., 2011; Xin et al., 2018). Equally important, sustained high-level antigen supply for continuous B cell receptor signaling fosters potent GC B cell responses and likely is accountable for more sustained ASC output in rCl13-infected animals.

Our observations help understand why nAbs to LCMV in mice, in analogy to HIV and HCV in humans, are more readily elicited in chronic infection than upon acute infection or vaccination (Eschli et al., 2007; Kinchen et al., 2018; Law et al., 2013; Osburn et al., 2014; Pestka et al., 2007; Pinschewer et al., 2004; Raghuraman et al., 2012; Rose et al., 2000; Rusert et al., 2016; Sommerstein et al., 2015). One widely held concept relates to the longer evolutionary trajectory of B cell receptors, which result from prolonged antigenic stimulation and continuous affinity maturation (Burton and Hangartner, 2016). Our findings of comparable BCR hypermutation rates in chronically and acutely infected mice, although not contradictory to the above, suggest that additional mechanisms may be at work. (1) We propose that the continuously high ASC output even at late time points after the onset of chronic infection warrants a better representation of the hypermutated GC B cell repertoire in the circulating serum antibody pool. Conversely, the hypermutated B cell pool emerging from acute infection would merely be available for accelerated nAb formation upon re-infection (Gage et al., 2019; Schweier et al., 2019). The observation that not only rCl13-infected, but also a few rARM-infected, mice mounted nAb responses (Figure 1C, right panel), supports this concept. It demonstrates that B clones of neutralizing capacity can be generated in acute infection, as well. (2) A second independent element that we assume is favoring nAb formation in chronic infection consists of the elevated cellularity of the GC B cell response. Studies in HIV-infected children, as well as the search for minimally mutated HIV-bnAbs, suggest that neutralizing B cell clones may be the product of a few serendipitous, yet improbable, mutations, rather than of accumulated mutational load (Georgiev et al., 2014; Jardine et al., 2016; Simonich et al., 2016; Wiehe et al., 2018). Similarly, HCV-bnAbs can apparently be generated with a limited number of critical somatic mutations (Bailey et al., 2017). A large pool of randomly mutated and efficiently selected B cell clones is, therefore, most likely to readily yield a few potently neutralizing ones. In line with that mechanism, the accompanying paper describes the chronic infection that results in greater intra-clonal diversification of responding B cells than in acute infection. (3) The combination of multiple weakly neutralizing antibodies can synergistically create substantial neutralizing activity (Mankowski et al., 2018; Nowakowski et al., 2002; Zwick et al., 2001). Based on greater cellularity of the GC response and greater diversification (see above and accompanying paper), we expect chronic infection to yield a broader spectrum of virus-specific serum antibodies and, therefore, more synergy-based neutralizing activity than acute infection produces.

A limitation of our study consists in its focus on B cells, without a concomitant analysis of CD4 T cell responses. During the past years, however, a series of elegant studies have investigated the key contribution of Tfh cells to GC B cell responses in chronic LCMV infection, documenting also their effect on virus control (Greczmiel et al., 2017; Harker et al., 2011; Xin et al., 2018). Further, we acknowledge that our study focuses on the late stages of infection, i.e., from 3 weeks after infection onward. That choice was based on the late appearance of nAbs in rCl13-infected mice, with an intention to better understand the B cell correlate thereof. Accordingly, the present study complements previous reports from our laboratory and from others, which have investigated B cell responses at the onset of LCMV infection (Fallet et al., 2016; Moseman et al., 2016; Sammicheli et al., 2016). Finally, LCMV infection in mice represents a versatile model to investigate the effect of chronic antigen load on immune responses, whereas other features of human infections, such as the progressive loss of CD4+ T cells in human HIV infection, are not recreated in the LCMV model but may also affect B cell responses.

In summary, our findings and those in the accompanying paper characterize GC B cell responses as an imperturbable element of antiviral defense, which operates effectively and even excels when continuously faced with high amounts of viral antigen. Thereby our study portrays the natural context in which GC B cell responses yield potent nAbs or even bnAbs against persisting viruses, depicting also the challenges yet to be met when attempting to safely mimic those processes for prophylactic vaccination.

STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- LEAD CONTACT AND MATERIALS AVAILABILITY
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Mice and Ethics Statement
  - Viruses and Cell Lines
- METHOD DETAILS
  - Flow Cytometry and Cell Sorting
  - Adoptive B Cell Transfer, Tamoxifen, and Passive Antibody Administration
  - Immunohistochemistry and Image Analysis
  - Viruses, Virus Production, Titration, and Infection
  - Determination of Neutralizing Antibody Titers
  - Analysis of Somatic Mutations at the IgH Locus
  - High Throughput Sequencing
  - Enzyme-Linked Immunosorbent Assay (ELISA), Recombinant Proteins, and Monoclonal Antibodies
  - Monoclonal Antibodies
- QUANTIFICATION AND STATISTICAL ANALYSIS
  - ELISA Quantification and Curve Fitting
  - Statistical Analysis
- DATA AND CODE AVAILABILITY
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.celrep.2019.12.025.

ACKNOWLEDGMENTS
We wish to thank Kerstin Narr for helpful discussions and long-standing collaboration, Bénédicte Alfonso for excellent technical assistance, Tatiana Fadeev for help with analysis of KL25 mutations, Karsten Stauffer for animal husbandry, and the DBM flow cytometry core facility for fluorescence-activated cell sorting (FACS). This work was supported by the European Research Council (ERC grants No. 310962 to D.D.P. and No. 693267 to C.-A.R.), by the Swiss National Science Foundation (project grants No. 310030_173132 to D.D.P. and No. 310030_173010 to D.M., and project No. 323630_151472 to B.F.), by SystemsX.ch-AntibodyX RTD (to S.T.R.), and by the Fondation Princesse Grace de Monaco (to J.-C.W.).

AUTHOR CONTRIBUTIONS

DECLARATION OF INTERESTS
D.D.P. is a founder, shareholder, and consultant and serves as chief scientific officer of Hookipa Pharma Inc., which is commercializing arenavirus-based vector technology. D.M. and D.D.P. are inventors on patents describing arenavirus-based vector technology. The remaining authors declare no competing interests.

Received: June 24, 2019
Accepted: December 6, 2019
Published: January 28, 2020

REFERENCES


and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J. Virol. 74, 10903–10910.


## STAR METHODS

### KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibodies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VL4 Rat anti-LCMV-NP</td>
<td>Dr. D.D. Pinschewer (Battegay et al., 1991)</td>
<td>N/A</td>
</tr>
<tr>
<td>Goat anti-Rat IgG-HRP</td>
<td>Jackson Immunoresearch</td>
<td>Cat#112-035-003; RRID: AB_2338128</td>
</tr>
<tr>
<td>Goat anti-Human IgG, Fc gamma-specific</td>
<td>Jackson Immunoresearch</td>
<td>Cat#109-005-098; RRID: AB_2337541</td>
</tr>
<tr>
<td>Goat anti-mouse IgG-HRP</td>
<td>Jackson Immunoresearch</td>
<td>Cat#115-035-205; RRID: AB_2338513</td>
</tr>
<tr>
<td>WEN-1</td>
<td>Dr. D.D. Pinschewer (Eschli et al., 2007)</td>
<td>N/A</td>
</tr>
<tr>
<td>WEN-3</td>
<td>Dr. D.D. Pinschewer (Seiler et al., 1998)</td>
<td>N/A</td>
</tr>
<tr>
<td>WEN-1UA</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>WEN-3UA</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>MOPC-21</td>
<td>BioXcell</td>
<td>Cat#BE0083; RRID: AB_1107784</td>
</tr>
<tr>
<td>KL25</td>
<td>Dr. D.D. Pinschewer (Bruns et al., 1983)</td>
<td>N/A</td>
</tr>
<tr>
<td>KL25-W104L</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>KL25-F108L</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>KL25-Y108S</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>Anti-mouse CD138 BV605</td>
<td>Biolegend</td>
<td>Cat#142516; RRID: AB_2562337</td>
</tr>
<tr>
<td>Anti-mouse B220 PE</td>
<td>BD Biosciences</td>
<td>Cat#553088; RRID: AB_394619</td>
</tr>
<tr>
<td>Anti-mouse IgM PercP-e710</td>
<td>eBioscience</td>
<td>Cat#46-5790-82; RRID: AB_1834435</td>
</tr>
<tr>
<td>Anti-mouse IgD APCy7</td>
<td>BioLegend</td>
<td>Cat#405716; RRID: AB_10662544</td>
</tr>
<tr>
<td>Anti-mouse GL-7 eF450</td>
<td>eBioscience</td>
<td>Cat#48-5902-82; RRID: AB_10870775</td>
</tr>
<tr>
<td>Anti-mouse B220 PECy7</td>
<td>BioLegend</td>
<td>Cat#103222; RRID: AB_313005</td>
</tr>
<tr>
<td>Anti-mouse GL-7 AF647</td>
<td>BioLegend</td>
<td>Cat#144606; RRID: AB_2562185</td>
</tr>
<tr>
<td>Anti-mouse CD95 PE</td>
<td>BD Biosciences</td>
<td>Cat#554258; RRID: AB_395330</td>
</tr>
<tr>
<td>Anti-mouse CD45.1 BV785</td>
<td>BioLegend</td>
<td>Cat#110743; RRID: AB_2563379</td>
</tr>
<tr>
<td>Anti-mouse CD45.2 AF700</td>
<td>BioLegend</td>
<td>Cat#109822; RRID: AB_493731</td>
</tr>
<tr>
<td>Anti-mouse CD95 PECy7</td>
<td>BD Biosciences</td>
<td>Cat#557653; RRID: AB_396768</td>
</tr>
<tr>
<td>Anti-mouse B220 AF700</td>
<td>BioLegend</td>
<td>Cat#103232; RRID: AB_493717</td>
</tr>
<tr>
<td>Ani-mouse CD45.1 PE</td>
<td>BD Biosciences</td>
<td>Cat#553776; RRID: AB_395044</td>
</tr>
<tr>
<td>Anti-mouse CD45.2 BV785</td>
<td>BioLegend</td>
<td>Cat#109839; RRID: AB_2562604</td>
</tr>
<tr>
<td>Anti-mouse B220 FITC</td>
<td>BD Bioscience</td>
<td>Cat#553088; RRID: AB_394618</td>
</tr>
<tr>
<td>Anti-mouse CD3 FITC</td>
<td>BD Bioscience</td>
<td>Cat#553088; RRID: AB_394594</td>
</tr>
<tr>
<td>Anti-mouse CD45.1 Biotin</td>
<td>BioLegend</td>
<td>Cat#110703; RRID: AB_313492</td>
</tr>
<tr>
<td>Biotinylated Peanut Agglutinin (PNA)</td>
<td>Vector Laboratories</td>
<td>Cat#B-1075; RRID:AB_2313597</td>
</tr>
<tr>
<td><strong>Anti-mouse CD38 PerCP/Cy5.5</strong></td>
<td>BioLegend</td>
<td>Cat#102721; RRID: AB_2563332</td>
</tr>
<tr>
<td>Polyclonal rat IgG</td>
<td>BioXcell</td>
<td>Cat#BE0094; RRID: AB_1107795</td>
</tr>
<tr>
<td>Anti-GFP Antibody</td>
<td>ICL</td>
<td>Cat#RGFP-45ALY-Z</td>
</tr>
<tr>
<td>Anti-mouse B220 Alexa Fluor 647</td>
<td>BioLegend</td>
<td>Cat#103226; RRID: AB_389330</td>
</tr>
<tr>
<td>PNA Alexa Fluor 488</td>
<td>ThermoFischer Scientific</td>
<td>Cat#L21409; RRID: AB_2315178</td>
</tr>
<tr>
<td>Anti-mouse CD16/CD32</td>
<td>BioXcell</td>
<td>Cat#BE0307; RRID: AB_2736987</td>
</tr>
<tr>
<td><strong>Bacterial and Virus Strains</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LCMV rCII3</td>
<td>Dr. D.D. Pinschewer (Flatz et al., 2006)</td>
<td>N/A</td>
</tr>
<tr>
<td>LCMV rARM</td>
<td>Dr. D.D. Pinschewer</td>
<td>N/A</td>
</tr>
</tbody>
</table>

(Continued on next page)
<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>LCMV rCl13*</td>
<td>Dr. D.D. Pinschewer (Hangartner et al., 2006)</td>
<td>N/A</td>
</tr>
<tr>
<td>LCMV rARM*</td>
<td>Dr. D.D. Pinschewer (Hangartner et al., 2006)</td>
<td>N/A</td>
</tr>
<tr>
<td>Vaccinia virus</td>
<td>Dr. D.D. Pinschewer (Pinschewer et al., 1999)</td>
<td>N/A</td>
</tr>
<tr>
<td>Vesicular stomatitis virus</td>
<td>Dr. D.D. Pinschewer (Charan et al., 1987)</td>
<td>N/A</td>
</tr>
</tbody>
</table>

### Chemicals, Peptides, and Recombinant Proteins

<table>
<thead>
<tr>
<th>Heparin Na 25000 I.E./5 ml</th>
<th>B. Braun Medical</th>
<th>Cat#B01AB01</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAB</td>
<td>DAKO</td>
<td>Cat#K5001</td>
</tr>
<tr>
<td>ABTS</td>
<td>Thermo Scientific</td>
<td>Cat#34026</td>
</tr>
<tr>
<td>Collagenase D</td>
<td>Roche</td>
<td>Cat#11088858001</td>
</tr>
<tr>
<td>DNasel</td>
<td>Calbiochem</td>
<td>Cat#260913</td>
</tr>
<tr>
<td>TRI reagent LS</td>
<td>Sigma-Aldrich</td>
<td>Cat#T3934-100ML</td>
</tr>
<tr>
<td>Tactin-XT</td>
<td>Iba</td>
<td>N/A</td>
</tr>
<tr>
<td>Tamoxifen-NOLVADEX</td>
<td>AstraZeneca</td>
<td>N/A</td>
</tr>
<tr>
<td>Clinolecic</td>
<td>Baxter</td>
<td>Cat#FDB9501</td>
</tr>
<tr>
<td>Tissue-freezing-medium</td>
<td>Leica Microsystems</td>
<td>Cat#14020108926</td>
</tr>
<tr>
<td>GP-1-Fc</td>
<td>Dr. D.D. Pinschewer (Eschli et al., 2007)</td>
<td>N/A</td>
</tr>
<tr>
<td>WE-GP-Fc</td>
<td>Dr. D.D. Pinschewer (Hangartner et al., 2006)</td>
<td>N/A</td>
</tr>
<tr>
<td>WE-GP*-Fc</td>
<td>Dr. D.D. Pinschewer (Hangartner et al., 2006)</td>
<td>N/A</td>
</tr>
<tr>
<td>WE-GP-StreptagII</td>
<td>Dr. D.D. Pinschewer (Sommerstein et al., 2015)</td>
<td>N/A</td>
</tr>
<tr>
<td>LCMV-NP</td>
<td>Dr. D.D. Pinschewer (Fallet et al., 2016)</td>
<td>N/A</td>
</tr>
<tr>
<td>Brilliant Violet 605 Streptavidin</td>
<td>BioLegend</td>
<td>Cat#405229; RRID:AB_2313597</td>
</tr>
</tbody>
</table>

### Critical Commercial Assays

<table>
<thead>
<tr>
<th>Zombie UV fixable viability kit</th>
<th>BioLegend</th>
<th>Cat#423108</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zombie Yellow fixable viability kit</td>
<td>BioLegend</td>
<td>Cat#423103</td>
</tr>
<tr>
<td>Alexa Fluor 647 Antibody Labeling Kit</td>
<td>Thermo Fischer Scientific</td>
<td>Cat#A20186</td>
</tr>
<tr>
<td>CellTrace Violet Cell Proliferation kit</td>
<td>Invitrogen</td>
<td>Cat#C34557</td>
</tr>
<tr>
<td>Pan B Cell Isolation Kit</td>
<td>Miltenyi Biotec</td>
<td>Cat#130-095-813</td>
</tr>
<tr>
<td>AccuScript High-Fidelity Reverse Transcriptase</td>
<td>Agilent Technologies</td>
<td>Cat#200820</td>
</tr>
<tr>
<td>TOPO-TA cloning kit</td>
<td>Invitrogen</td>
<td>Cat#450641</td>
</tr>
<tr>
<td>SPI select beads</td>
<td>Beckman Coulter</td>
<td>Cat#833319</td>
</tr>
<tr>
<td>KAPA Library Quantification Kit</td>
<td>KAPA Biosystems</td>
<td>Cat#KK4824</td>
</tr>
<tr>
<td>High Sensitivity NGS Fragment Analysis Kit</td>
<td>Advanced Analytical</td>
<td>Cat#DNF-474-1000</td>
</tr>
<tr>
<td>Q5 Hot Start High-Fidelity DNA polymerase</td>
<td>NEB</td>
<td>Cat#M0493</td>
</tr>
<tr>
<td>Vector® TrueVIEW Autofluorescence Quenching Kit</td>
<td>Vector Laboratories</td>
<td>Cat#SP-8400</td>
</tr>
<tr>
<td>Anti-biotin MicroBeads</td>
<td>Miltenyi Biotec</td>
<td>Cat#130-090-485</td>
</tr>
</tbody>
</table>

### Deposited Data

| High-throughput B cell receptor sequencing data | NCBI Bioproject | Acc#PRJNA579837 |

### Experimental Models: Cell Lines

<table>
<thead>
<tr>
<th>Hamster: BHK-21</th>
<th>ECACC</th>
<th>Cat#85011433; RRID: CVCL_1915</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse: NIH 3T3</td>
<td>ATCC</td>
<td>Cat#CRL-1658; RRID:CVCL_0594</td>
</tr>
</tbody>
</table>

(Continued on next page)
**LEAD CONTACT AND MATERIALS AVAILABILITY**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Daniel D. Pinschewer (Daniel.Pinschewer@unibas.ch). Material transfer agreements with standard academic terms will be established to document reagent sharing.

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Experimental Models: Organisms/Strains</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse: C57BL/6</td>
<td>The Jackson laboratory</td>
<td>JAX: 000664</td>
</tr>
<tr>
<td>Mouse: AID-Cre-EYFP, Aicdatm1.1(cre/ER2)Cre x Gt(Rosa)26Sortm1(EYFP)C0s</td>
<td>Dr. J.C. Weill (Dogan et al., 2009)</td>
<td>N/A</td>
</tr>
<tr>
<td>Mouse: KL25HL; B6-IgH-J &lt; tm1(VDJ-KL25)Zbz x B6J-Tg(KL25L)Tac</td>
<td>Dr. D.D. Pinschewer (Fallet et al., 2016)</td>
<td>N/A</td>
</tr>
<tr>
<td>Mouse: KL25L; B6J-Tg(KL25L)Tac</td>
<td>Dr. D.D. Pinschewer (Fallet et al., 2016)</td>
<td>N/A</td>
</tr>
<tr>
<td>Mouse: KL25HL-AID&lt;sup&gt;465&lt;/sup&gt;, Aicdatm1.1(cre/ER2)Cre x Gt(Rosa)26Sortm1(EYFP)C0s x B6-IgH-J &lt; tm1(VDJ-KL25)Zbz x B6J-Tg(KL25L)Tac</td>
<td>This Paper</td>
<td>N/A</td>
</tr>
<tr>
<td>Mouse: AID&lt;sup&gt;465&lt;/sup&gt;; B6(Cg)-Aicda &lt; tm2.1Hon &gt;</td>
<td>Dr. T.Honjo (Wei et al., 2011)</td>
<td>N/A</td>
</tr>
<tr>
<td>Mouse: AID&lt;sup&gt;465&lt;/sup&gt;; B6(Cg)-Aicda &lt; tm2.1Hon &gt; x Aicdatm1.1(cre/ER2)Cre</td>
<td>Dr. T.Honjo (Wei et al., 2011)</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Oligonucleotides</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VH1: GAGGACTCTGCRGTCTATTWC</td>
<td>This Paper</td>
<td>N/A</td>
</tr>
<tr>
<td>VH3: GAGGACACACCCACATATTAC</td>
<td>This Paper</td>
<td>N/A</td>
</tr>
<tr>
<td>VH5: GAGGACACRGCCATGTATTAC</td>
<td>This Paper</td>
<td>N/A</td>
</tr>
<tr>
<td>VH6: GAAGACACCTGGAATTTATTAC</td>
<td>This Paper</td>
<td>N/A</td>
</tr>
<tr>
<td>VH7: GAGGACAGTGGCATTATTAC</td>
<td>This Paper</td>
<td>N/A</td>
</tr>
<tr>
<td>VH9: ATGAGGACATGGCTACATATTTC</td>
<td>This Paper</td>
<td>N/A</td>
</tr>
<tr>
<td>JH4rev: CACCAGACCTCTCTAGACAGC</td>
<td>This Paper</td>
<td>N/A</td>
</tr>
<tr>
<td>JH4-nested: TGAAGACACCTGCTAGC</td>
<td>This Paper</td>
<td>N/A</td>
</tr>
<tr>
<td>VHDJH2: 5' primer: CTCTCCGACGGGTCCACTCC</td>
<td>This Paper</td>
<td>N/A</td>
</tr>
<tr>
<td>VHDJH2: 3' primer: AGAAAGAGGTGTTGAAGGACTCAC</td>
<td>This Paper</td>
<td>N/A</td>
</tr>
<tr>
<td>JH2-JH4 segment: 5' primer: CTCGGACACACTC TACAGGT</td>
<td>This Paper</td>
<td>N/A</td>
</tr>
<tr>
<td>JH2-JH4 segment: 3' primer: CACCAGACCTCTCTAGACAGC</td>
<td>This Paper</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Recombinant DNA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse HC IgG1 expression plasmid</td>
<td>Dr. Shozo Izui</td>
<td>N/A</td>
</tr>
<tr>
<td>Mouse LC expression plasmid</td>
<td>Dr. Shozo Izui</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Software and Algorithms</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GEN5</td>
<td>BioTek Instruments</td>
<td>RRID: SCR_017317</td>
</tr>
<tr>
<td>GraphPad Prism 7</td>
<td>GraphPad Software</td>
<td>RRID: SCR_002798</td>
</tr>
<tr>
<td>FlowJo</td>
<td>Tree Star</td>
<td>RRID: SCR_008520</td>
</tr>
<tr>
<td>Illumina MiSeq System</td>
<td>Illumina MiSeq</td>
<td>RRID: SCR_016379</td>
</tr>
<tr>
<td>PANDAseq</td>
<td>Panda</td>
<td>RRID: SCR_002705</td>
</tr>
<tr>
<td>CodonCode aligner</td>
<td>CodonCode Corporation</td>
<td>N/A</td>
</tr>
<tr>
<td>IMGT/LIGM-DB</td>
<td>IMGT/LIGM-DB</td>
<td>RRID: SCR_006931</td>
</tr>
<tr>
<td>IgBlast</td>
<td>IgBlast</td>
<td>RRID: SCR_002873</td>
</tr>
<tr>
<td>Adobe Photoshop CS6</td>
<td>Adobe Photoshop</td>
<td>RRID: SCR_014199</td>
</tr>
</tbody>
</table>
EXPERIMENTAL MODEL AND SUBJECT DETAILS

Mice and Ethics Statement
C57BL/6J wild-type mice were purchased from Charles River, France, CD45.1-congenic C57BL/6J have been obtained from the Swiss Immunological Mouse Repository, (SwimMR), AID-Cre-EYFP (AID<sup>rep</sup>) mice carrying a targeted tamoxifen- (TAM-) inducible Cre recombinase (Cre-ERT2) in the aicda locus in combination with a Cre-inducible EYFP reporter gene in the ROSA26 locus have been described (Dogan et al., 2009). KL25HL mice, which express the monoclonal LCMV envelope-specific B cell receptor KL25 from a heavy chain knock-in and a light chain transgene, and KL25L mice, which express the light chain of the monoclonal LCMV envelope-specific B cell receptor KL25 as a transgene have been described (Fallet et al., 2016). KL25HL-AID<sup>rep</sup> mice have been obtained by crossing AID-Cre-EYFP mice with KL25HL mice. AID<sup>G23S</sup> mice (carrying a targeted G23S mutation on the aicda locus) were generously provided by Dr. T. Honjo (Wei et al., 2011). F1 offspring resulting from the intercross of homozygous AID<sup>G23S</sup> and homozygous AID-Cre-EYFP mice were used as hypermutation-impaired AID<sup>G23S/-</sup> mice for experiments. All mice were on a C57BL/6 background and were bred at the Laboratory Animal Science Center (LASC) of the University of Zurich, Switzerland, under specific pathogen-free (SPF) conditions. Experiments were performed at the University of Basel and at the University of Geneva, in accordance with the Swiss law for animal protection and with authorizations from the Veterinäramt Basel-Stadt and from the Direction Générale de la Santé, Domaine de l’Expérimentation Animale of the Canton of Geneva, respectively. Assignment to experimental groups was based on sex- and age-matching. Adult animals of both genders were used to reduce the number of animals bred for research purposes. Study sample sizes in mouse experiments were chosen based on experience in our labs with respect to group sizes readily revealing biologically significant differences in the experimental models used. The groups were neither randomized nor were experiments conducted in a blinded fashion.

Viruses and Cell Lines
The recombinant LCMV strain CI13 (rCI13) and Armstrong (rARM) expressing the surface glycoprotein of the LCMV strain WE (WE-GP) and the WE-GP N121K variants (rCI13<sup>*,</sup> rARM<sup>**</sup>) have been described (Sommerrstei et al., 2015) and were engineered by standard procedures (Flatz et al., 2006). Recombinant Vaccinia virus expressing VSVG and vesicular stomatitis virus serotype Indiana (VSV) have been described (Charan et al., 1987; Pinschewer et al., 1999). For virus production and titration BHK-21 cells (Clone 13, ECAAC), BSC40 cells (ATCC) and NIH 3T3 cells (ATCC) were used and were confirmed to be mycoplasma-negative. Owing to their origin from renowned international repositories they were not authenticated.

METHOD DETAILS

Flow Cytometry and Cell Sorting
Single cell suspensions were obtained from spleens by mechanical or enzymatic digestion. Spleens were harvested in PBS containing 5% FCS and for mechanical digestion spleens pushed through a metal mesh in a Petri dish and homogenized by pipetting. For enzymatic digestion spleens where cut into small pieces and incubated with collagenase D (Roche) and DNaseI (Calbiochem) at 37°C in 5% FCS and for mechanical digestion spleens pushed through a metal mesh in a Petri dish and homogenized by pipetting. Single cell suspensions were obtained from spleens by mechanical or enzymatic digestion. Spleens were harvested in PBS containing 5% FCS and for mechanical digestion spleens pushed through a metal mesh in a Petri dish and homogenized by pipetting. For enzymatic digestion spleens where cut into small pieces and incubated with collagenase D (Roche) and DNaseI (Calbiochem) at 37°C in 5% FCS and for mechanical digestion spleens pushed through a metal mesh in a Petri dish and homogenized by pipetting. For virus production and titration BHK-21 cells (Clone 13, ECAAC), BSC40 cells (ATCC) and NIH 3T3 cells (ATCC) were used and were confirmed to be mycoplasma-negative. Owing to their origin from renowned international repositories they were not authenticated.

Cell sorting was performed using a FACSria II cell sorter (Becton Dickinson).
Adoptive B Cell Transfer, Tamoxifen, and Passive Antibody Administration

For adoptive transfer of CD45.1+ KL25HL-AID<sup>eoe</sup> B cells, CellTrace Violet (Invitrogen) -labeled bulk splenocytes (2 x 10<sup>6</sup> cells per recipient) or purified B cells (2 x 10<sup>6</sup> cells per recipient) were injected intravenously in balance salt solution. B cells were purified by magnetic activated cell sorting using the Pan B Cell Isolation Kit for untouched B cells (Miltenyi Biotec). Syngenic (CD45.2+) C57BL/6J mice served as recipients for short-term transfers. Transfers of KL25HL cells for analysis >1 week later were performed in KL25L recipients to avoid rejection by anti-idiotypic responses (Fallet et al., 2016).

For adoptive transfer of Vaccinia virus- or LCMV-experienced EYFP<sup>+</sup> B cells we infected AID<sup>eoe</sup> mice on day 0 with the respective viruses, followed by tamoxifen treatment on day 0, 5 and 10. On day 30 splenic B cells were MACS-purified (Miltenyi Biotec Pan B Cell Isolation Kit for untouched B cells) and labeled with CTV. 2 x 10<sup>6</sup> – 8 x 10<sup>6</sup> B cells (purity >95%) containing between 10<sup>5</sup> – 1.5 x 10<sup>5</sup> EYFP<sup>+</sup> cells were transferred into Vaccinia virus- or LCMV-infected CD45.1+congenic C57BL/6J recipients.

Tamoxifen (2.5 mg Novadex (AstraZeneca) in 20% Clinoleic (Baxter)) was administered by gavage.

Passive antibody administration was performed three days after infection by an intravenous bolus injection of 300 μg purified antibody in PBS.

Immunohistochemistry and Image Analysis

For the histological sections shown in Figure 3, tissues were fixed in PBS containing 4% paraformaldehyde (Merck) for at least 4 hours at 4°C, then washed with PBS and cryoprotected with PBS-30% sucrose (Sigma-Aldrich) for at least 2 hours at 4°C. Tissues were then embedded in Tissue-freezing-medium (Leica Microsystems) and frozen on dry ice. For the microsections shown on Figure 4, tissues were fixed in PBS containing 4% paraformaldehyde (Merck) for at least 4 hours at 4°C, then washed with PBS and embedded in paraffin. Immunostaining was performed on 3 μm-thick sections using antibodies against GFP (ICL lab), Alexa Fluor 647-directly labeled B220 (eBioscience) and Lectin PNA Alexa Fluor 488 Conjugate (ThermoFisher). Immunostained slides were incubated with the Vector® TrueVIEW Autofluorescence Quenching Kit to remove autofluorescence signal (Vector Laboratories). Stained sections were scanned using a Panoramic Digital Slide Scanner 250 FLASH II (3DHISTECH) at 200 x magnification. Contrast was adapted using the “levels,” “curves,” “brightness” and “contrast” tools in Photoshop CS6.

Viruses, Virus Production, Titration, and Infection

For LCMV batch production, BHK-21 cells (ATCC) were infected with the respective viruses at MOI = 0.01 and virus-containing supernatant was harvested 48 hours later.

Recombinant Vaccinia virus expressing VSVG was produced on BSC-40 cells and vesicular stomatitis virus serotype Indiana (VSV) was grown on BHK-21 cells (MOI = 0.01 for 24 hours) (Pinschewer et al., 1999).

LCMV infectivity in blood was determined by immunofocus assay (Battegay et al., 1991). In brief, blood was collected into BSS supplemented with 1 IE/ml heparin (Na-heparin, Braun). Ten-fold serial dilutions were performed and were mixed with NIH 3T3 cells (ATCC) in 24-well plates, followed by 3 hours of incubation at 37°C. Then, overlay (1% methylcellulose in DMEM) was added and the cultures were incubated for two days. On the third day, supernatant was removed, the cells were fixed with 4% paraformaldehyde and permeabilized (1% Triton X-100 in PBS). After blocking (5% FCS), infectious foci were visualized using VL4 rat-anti-LCMV-NP antibody and secondary HRP-conjugated goat-anti-rat-IgG (Jackson Immunoresearch), followed by a color reaction (DAB).

rARM and rARM* infections were performed by intraperitoneal (i.p.) injection of 200 plaque-forming units (PFU). rCl13 and rCl13* were administrated intravenously (i.v.) at a dose of 2x10<sup>8</sup> – 4x10<sup>8</sup> PFU. Vaccinia virus and VSV were administrated i.v. at doses of 2x10<sup>6</sup> and 2x10<sup>7</sup> PFU, respectively.

Determination of Neutralizing Antibody Titers

Neutralizing antibodies were measured in standard immunofocus assay-based (Battegay et al., 1991) plaque reduction neutralization tests. Serial two-fold dilutions of antibody-containing sera and of purified monoclonal antibodies were conducted in MEM 2% FCS in a 96-well format. Approximately 50 PFU of virus was added to each well, followed by 90 minutes of incubation at 37°C. NIH 3T3 fibroblasts were added and incubated with the virus – antibody mixture at 37°C for 90 minutes, allowing the cells to adhere. Thereafter, overlay (1% methylcellulose in DMEM) was added. Two days later, infectious foci were identified as described for the LCMV immunofocus assay. Neutralizing titers in mouse sera were determined as the highest serum dilution yielding at least 50% focus formation reduction. For monoclonal antibodies, the number of infectious foci at a given antibody concentration was expressed as a percent-age of the number of foci in control wells without antibody added.

Analysis of Somatic Mutations at the IgH Locus

The J<sub>H</sub>4 intronic sequence flanking rearranged V<sub>H</sub> gene segments was amplified by PCR from DNA of sorted B cell subsets, from 10,000 to 1,000,000 cells. The PCR primers used are: in 5’, a mixture of five FR3 primers amplifying most V<sub>H</sub> gene families (V<sub>H</sub>1:; GAG GACTCTGCRGTCTATTWC, V<sub>H</sub>3: GAGGACAACCCACCATATTAC, V<sub>H</sub>5: GAGGACACRGCCATGTATTAC, V<sub>H</sub>6: GAAGACACTGG AATTATTAC, V<sub>H</sub>7: GAGGACAGTGCCACTATTAC, V<sub>H</sub>8: ATGAGGACAGTGGCTACATTTTC, in a 6:1:3:1:1 ratio); in 3’, a J<sub>H</sub>4 intronic primer (J<sub>H</sub>4rev: CACCAGACCTCTCTAGACAGC), with a nested amplification performed in cases of low cell numbers (using J<sub>H</sub>4-nested: TGAGACCGAGGGCTAGTGC and the same V<sub>H</sub> primer set) (2 min at 98°C and 50 cycles of 15 s at 98°C, 30 s at 64°C, a 96-well format. Approximately 50 PFU of virus was added to each well, followed by 90 minutes of incubation at 37°C. NIH 3T3 fibroblasts were added and incubated with the virus – antibody mixture at 37°C for 90 minutes, allowing the cells to adhere. Thereafter, overlay (1% methylcellulose in DMEM) was added. Two days later, infectious foci were identified as described for the LCMV immunofocus assay. Neutralizing titers in mouse sera were determined as the highest serum dilution yielding at least 50% focus formation reduction. For monoclonal antibodies, the number of infectious foci at a given antibody concentration was expressed as a percent-age of the number of foci in control wells without antibody added.

Analysis of Somatic Mutations at the IgH Locus

The J<sub>H</sub>4 intronic sequence flanking rearranged V<sub>H</sub> gene segments was amplified by PCR from DNA of sorted B cell subsets, from 10,000 to 1,000,000 cells. The PCR primers used are: in 5’, a mixture of five FR3 primers amplifying most V<sub>H</sub> gene families (V<sub>H</sub>1:; GAG GACTCTGCRGTCTATTWC, V<sub>H</sub>3: GAGGACAACCCACCATATTAC, V<sub>H</sub>5: GAGGACACRGCCATGTATTAC, V<sub>H</sub>6: GAAGACACTGG AATTATTAC, V<sub>H</sub>7: GAGGACAGTGCCACTATTAC, V<sub>H</sub>8: ATGAGGACAGTGGCTACATTTTC, in a 6:1:3:1:1 ratio); in 3’, a J<sub>H</sub>4 intronic primer (J<sub>H</sub>4rev: CACCAGACCTCTCTAGACAGC), with a nested amplification performed in cases of low cell numbers (using J<sub>H</sub>4-nested: TGAGACCGAGGGCTAGTGC and the same V<sub>H</sub> primer set) (2 min at 98°C and 50 cycles of 15 s at 98°C, 30 s at 64°C, a 96-well format. Approximately 50 PFU of virus was added to each well, followed by 90 minutes of incubation at 37°C. NIH 3T3 fibroblasts were added and incubated with the virus – antibody mixture at 37°C for 90 minutes, allowing the cells to adhere. Thereafter, overlay (1% methylcellulose in DMEM) was added. Two days later, infectious foci were identified as described for the LCMV immunofocus assay. Neutralizing titers in mouse sera were determined as the highest serum dilution yielding at least 50% focus formation reduction. For monoclonal antibodies, the number of infectious foci at a given antibody concentration was expressed as a percent-age of the number of foci in control wells without antibody added.
and 30 s at 72 °C, with Phusion® DNA polymerase (New England Biolabs); or 30 cycles plus 25 additional cycles in cases of nested PCR). Mutations were determined within 448 base pairs of the JH4 intron.

For the KL25 VDJ knock-in allele, two different PCR were performed: one encompassing the VHDJH2 (V1-53) coding sequence, and the other one based on the flanking intronic sequence, consisting in a fused J2-J4 segment present in the knock-in construct, using the following conditions. VHDJH2: 5′ primer, CTCTCCGACAGTCTCCACTCC; 3′ primer, AGAAGAGGTGTGAAGACTCAC; J2-J4 segment: 5′ primer, CATTGCCACCTGCTCTAGACTC; 3′ primer, CAGGAGCTCTCTTAGAGACG (2 min at 98 °C and 40 cycles of 15 s at 98 °C, 30 s at 64 °C and 30 s at 72 °C). Mutations were determined for the 324 bp sequence of the V6 gene (including CDR3), and for 570 bp of the intronic sequence, immediately downstream of J2.

PCR products were cloned with the TOPO-TA cloning kit (Invitrogen) and sequences were determined with an ABI Prism 3130xl Genetic Analyzer. Mutations were analyzed with the help of the CodonCode Aligner software. Between 16 to 91 sequences per sample were determined for mutation frequency determination.

High Throughput Sequencing
Preparation of antibody libraries from rCl13-infected WT and AIDG23S/- mice: Library preparation by RT-PCR was performed similar to the protocol described in Menzel et al. (2014). Total RNA was extracted (25 μL elution volume) using the TRizol Plus RNA Purification Kit (Life Technologies) according to the manufacturer’s protocol. First-strand cDNA was synthesized with AccuScript High-Fidelity Reverse Transcriptase (Agilent Technologies) using total RNA and Oligo(dT) primers (Thermo Scientific) following the manufacturer’s instructions. PCR-amplification was performed with Q5 Hot Start High-Fidelity DNA polymerase (NEB) in 50 μL reaction volumes with adjusted cycle numbers. For the eight germinal center samples an IgG-specific reverse primer was used. PCR1 products were purified using SPRI select beads (Beckman Coulter) at a ratio of 0.8X (elution in 30 μL water). Purified PCR1 products were submitted to PCR2-amplification, which adds full-length Illumina adapters to the library. Final products were gel-purified from 1% agarose gels. All ampiclon libraries were quantified by qPCR using the KAPA Library Quantification Kit (KAPA Biosystems). Based on qPCR results, samples were diluted to 7 nM concentrations and a pool was prepared with equal amounts of library. Last, the pool was checked on a Fragment Analyzer (DNF-486 High Sensitivity NGS Fragment Analysis Kit, Advanced Analytical), the exact concentration determined (Qubit 2.0 Fluorometer) and diluted to a final concentration of 4 nM.

Illumina sequencing and data preprocessing: Illumina MiSeq sequencing was performed using 2x300 bp reads. Forward and reverse reads were paired using PANDAseq (Version 2.7, [2]) with parameter −0 300. Full-length VDJ region annotation and somatic mutation enumeration of successfully paired sequences was performed using ImMunoGeneTics (IMGT)/HighV-QUEST [3, 4]. For downstream analyses, sequences were pre-processed and reads only retained based on the following criteria: (i) the IMGT-indicated “Functionality” of the sequencing was “productive”; (ii) CDR3s were of minimal length of 4 amino acids; (iii) CDR3 were present with a minimum abundance of 2. Nucleotide mutation numbers were based on IMGT. Number of reads in analyses shown ranged between 1.3 and 1.5x10^6 per individual across both C57BL/6 and AIDG23S/- mice.

Enzyme-Linked Immunosorbent Assay (ELISA), Recombinant Proteins, and Monoclonal Antibodies
GP-1-binding antibodies in mouse serum were determined using recombinant HEK293 cell-derived GP-1-Fc fusion protein as a substrate (Eschli et al., 2007). Binding of KL25 and the affinity-matured mutants KL25-W104L, KL25-F106L and KL25-Y108S to WE-GP GP-1-binding antibodies in mouse serum were determined using recombinant HEK293 cell-derived GP-1-Fc fusion protein as a sub-

Enzyme-Linked Immnosorbtent Assay (ELISA), Recombinant Proteins, and Monoclonal Antibodies

The GP-binding capacity of WEN-1, WEN-1UA, WEN-3 and WEN-3UA was determined using as an ELISA substrate a HEK293-derived extracellular WE-GP domain with a C-terminal StreptagII sequence (GP-Streptag [Sommerstein et al., 2015]). The ELISA assay was performed analogously to the above, except that GP-Streptag was captured by coating ELISA plates with 0.5 ug/ml of Strept-TactinXT (Iba), and that the plates were blocked with 0.2% BSA in PBS.

Monoclonal Antibodies
The unmutated ancestor sequences (WEN-1UA, WEN-3UA) of the rCl13-neutralizing monoclonal antibodies WEN-1 and WEN-3 (Figure S1; [Eschli et al., 2007; Seiler et al., 1998]) were identified by IgBlast (IgBlast) sequence analysis. All mutations deviating from the closest germline V(D)J heavy (HC) and light chain (LC) sequences were reversed. The corresponding cDNAs were synthesized (Genscript) and introduced into HC and LC expression cassettes for recombinant expression in a mouse IgG1 format (provided by Dr. Shozo Izui, University of Geneva). The antibodies were produced by transient co-transfection of the HC and LC expression plasmids in CHO cells (Protein Expression Core Facility, PECF, of the Swiss Federal Technical Highschool, EPFL, Lausanne, Switzerland). The antibodies were purified on an ÄKTAPrime plus purification system using Protein G columns (GE healthcare). After
24 hours of PBS dialysis, the purified antibodies were quantified by IgG ELISA. MOPC-21 (BioXcell) served as isotype control antibody. The KL25-W104L, KL25-F106L and KL25-Y108S antibodies as well as a matching KL25 wild-type control antibody (Bruns et al., 1983) were obtained by analogous procedures, except that a mouse IgG2a expression format was used for these experiments.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

**ELISA Quantification and Curve Fitting**

For titer determination in mouse serum based on standard curve fit, GEN5 software (BioTek Instruments) was used. Binding and neutralization curves of monoclonal antibodies were fitted using GraphPad Prism software 7 (GraphPad Prism).

**Statistical Analysis**

The GraphPad Prism software version 7 (GraphPad Software) was used for all statistical analyses. Unpaired two-tailed Student’s t tests were performed to compare one parameter between two groups. For comparison of one parameter between multiple groups one-way analysis of variance (ANOVA) was performed and for comparison of multiple parameters between two or more groups two-way ANOVA was used, both followed by Bonferroni’s post-test for multiple comparison. For statistical analysis of absolute cell counts, values were log-converted to obtain a near-normal distribution. *P* values ≥ 0.05 were regarded as not statistically significant (ns), *p* values < 0.05 as significant (*, #) and *p* < 0.01 as highly significant (**, ##).

The number of experimental animals “n” per group, number of experimental repeats “N,” the type of error bar displayed and the tests performed for statistical analysis are indicated in each figure legend.

**DATA AND CODE AVAILABILITY**

High-throughput IgH sequencing data have been archived with the NCBI under BioProject number PRJNA579837. Additional raw datasets will be provided by the authors upon request.